University Hospital, Strasbourg, france
Strasbourg, 67000, France
NCT Number: NCT02472197
Intrauterine pathologies are currently treated by hysteroscopic resection. In this surgical procedure, the intrauterine pathology is resected by a transcervical approach in several fragments using a mono or bipolar cove after distension of the uterine cavity and by endoscopic control. The main risks of this surgery are: uterine perforation and OHIA (operative hysteroscopy intravascular absorption) syndrome. Hysteroscopic morcellators are new intrauterine devices, recently appeared on the French market.
In comparison to classical resectors, morcellators have several theoretical advantages:
* A smaller instrument diameter with potentially a lower risk of uterine perforation and cervical laceration during the dilatation procedure, * The use of physiological serum, eliminating the risk of neurological toxicity of glycine, * The risk of electrical accident is canceled (internal or external burns due to leakage current), * A decreased risk of air embolism, due to the absence of bubbles' production, * The instrument is always under visual control, the perforation risk by the active instrument is therefore very limited, * The vision is not obscured by the fragments or by the bubbles, * The treatment of pre-ostial pathologies, not always easy in classical resections, could be facilitated, * the absence of thermal effect, and therefore a potentially lower endometrial aggression, is interesting in women with reproductive desire, * Absence of chips management, limiting the entry and exit movements in the uterine cavity, improving the vision, reducing the infectious and traumatic risks, specially uterine perforation and air embolism, * Morcellation could preserve tissues for histological analysis of possible malignancy (compared to techniques using heat, coagulation, vaporization), * Easy learning in comparison to the time-consuming learning of classical hysteroscopic resection, * Generated additional cost could be partly amortized by reducing operating time and complications.
It seemed useful to study this new technology.
The primary purpose was to compare the time of hysteroscopic treatment of uterine polyps between a hysteroscopic morcellator the UNIDRIVE S III / DrillCut-X II-GYN-Shaver (Integrated Bigatti Shaver IBS), Storz®, and a conventional resectoscope.
The secondary purposes were to compare the efficiency, complications and comfort of these techniques.
Looking for future studies?
Notify Me18 year and older
Female
Interventional
Not applicable
Strasbourg, 67000, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The endometrial polyp is resected by a transcervical approach. During the procedure, the polyp is placed by suction against the window of the device, then cut by mechanical energy, in chips which are directly aspirated by the device.
The endometrial polyp is resected by a transcervical approach in several chips using a mono or bipolar cove after distension of the uterine cavity under endoscopic control.
Time frame: From the cervical dilatation just before introducing the operative device until removal of the operative device assessed up to 25 minutes
Time frame: 10 weeks after surgery
Time frame: from the beginning of diagnostic hysteroscopy to the end of operative hysteroscopy resection and removal of the operative device, assessed up to 25 minutes
Time frame: At the end of surgery
Time frame: 10 weeks after surgery
Time frame: At the end of surgery
Time frame: 10 weeks after surgery
evaluated by hysteroscopy
Time frame: 10 weeks after surgery
University Hospital, Strasbourg, France
Other
Acronym: RESMO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02520414
Connective Tissue Diseases, Endometrial Polyps
Albuquerque, New Mexico, United States
View Trial DetailsNCT02126397
Endometrial Polyps
Córdoba, Cordoba, Spain
View Trial DetailsNCT01509313
Endometrial Polyps
Birmingham, West Midlands, United Kingdom
View Trial DetailsNCT07074795
Abnormal Uterine Bleeding, Agnosia
Bnei Brak, Israel
View Trial Details